Anna Weis

Ms. Anna Weis


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AWAnna Weis
Anna Weis
LMLouise Marquart
Louise Marquart
DCDiego A. Calvopina
Diego A. Calvopina
BGBerit Genz
Berit Genz
Grant RammGrant Ramm
Grant Ramm
RSRichard Skoien
Richard Skoien
Early diagnosis of cirrhosis and hepatocellular carcinoma (HCC) due to chronic Hepatitis C (CHC) remain clinical priorities. In this pilot study, we assessed serum microRNA (miRNA) expression to distinguish cirrhosis and HCC, alone and in combination with the aminotransferase-to-platelet ratio (APRI), Fibrosis 4 (FIB-4), and alpha-fetoprotein (AFP). Sixty CHC patients were subdivided into 3 cohorts: Mild disease (fibrosis stage F0-2; n = 20); cirrhosis (n = 20); and cirrhosis with HCC (n = 20). Circulating miRNA signatures were determined using a liver-specific real-time quantitative reverse transcription PCR (qRT-PCR) microarray assessing 372 miRNAs simultaneously. Differentially-expressed miRNA candidates were independently validated using qRT-PCR. Serum miRNA-409-3p was increased in cirrhosis versus mild disease. In HCC versus cirrhosis, miRNA-486-5p was increased, whereas miRNA-122-5p and miRNA-151a-5p were decreased. A logistic regression model-generated panel, consisting of miRNA-122-5p + miRNA-409-3p, distinguished cirrhosis from mild disease (area under the curve, AUC = 0.80; sensitivity = 85%, specificity = 70%; p < 0.001). When combined with FIB-4 or APRI, performance was improved with AUC = 0.89 (p < 0.001) and 0.87 (p < 0.001), respectively. A panel consisting of miRNA-122-5p + miRNA-486-5p + miRNA-142-3p distinguished HCC from cirrhosis (AUC = 0.94; sensitivity = 80%, specificity = 95%; p < 0.001), outperforming AFP (AUC = 0.64, p = 0.065). Serum miRNAs are differentially expressed across the spectrum of disease severity in CHC. MicroRNAs have great potential as diagnostic biomarkers in CHC, particularly in HCC where they outperform the only currently-used biomarker, AFP.

12 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BGBerit Genz
Berit Genz
MCMiranda A. Coleman
Miranda A. Coleman
KIKatharine Irvine
Katharine Irvine
JKJamie Kutasovic
Jamie Kutasovic
MMMariska Miranda
Mariska Miranda
Grant RammGrant Ramm
Grant Ramm
During chronic liver injury hepatic stellate cells (HSCs), the principal source of extracellular matrix in the fibrotic liver, transdifferentiate into pro-fibrotic myofibroblast-like cells - a process potentially regulated by microRNAs (miRNAs). Recently, we found serum miRNA-25-3p (miR-25) levels were upregulated in children with Cystic Fibrosis (CF) without liver disease, compared to children with CF-associated liver disease and healthy individuals. Here we examine the role of miR-25 in HSC biology. MiR-25 was detected in the human HSC cell line LX-2 and in primary murine HSCs, and increased with culture-induced activation. Transient overexpression of miR-25 inhibited TGF-β and its type 1 receptor (TGFBR1) mRNA expression, TGF-β-induced Smad2 phosphorylation and subsequent collagen1α1 induction in LX-2 cells. Pull-down experiments with biotinylated miR-25 revealed Notch signaling (co-)activators ADAM-17 and FKBP14 as miR-25 targets in HSCs. NanoString analysis confirmed miR-25 regulation of Notch- and Wnt-signaling pathways. Expression of Notch signaling pathway components and endogenous Notch1 signaling was downregulated in miR-25 overexpressing LX-2 cells, as were components of Wnt signaling such as Wnt5a. We propose that miR-25 acts as a negative feedback anti-fibrotic control during HSC activation by reducing the reactivity of HSCs to TGF-β-induced collagen expression and modulating the cross-talk between Notch, Wnt and TGF-β signaling.

15 November 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
DCDiego A. Calvopina
Diego A. Calvopina
MCMark D. Chatfield
Mark D. Chatfield
AWAnna Weis
Anna Weis
MCMiranda A. Coleman
Miranda A. Coleman
MFManuel A. Fernandez‐Rojo
Manuel A. Fernandez‐Rojo
Grant RammGrant Ramm
Grant Ramm

1 January 2015
Verified
Book Chapter
Closed access
PDF file
AWAnna Weis
Anna Weis
FLFang Liang
Fang Liang
JGJing Gao
Jing Gao
RBRoss Thomas Barnard
Ross Thomas Barnard
SCSimon Robert Corrie
Simon Robert Corrie


1 July 2014 in Current Protocols in Cytometry
Verified
Journal Article
Open access
PDF file
LFLiang Fang
Liang Fang
AWAnna Weis
Anna Weis
LWLawrence Kurniawan Wong
Lawrence Kurniawan Wong
DYDavid Che‐Cheng Yeh
David Che‐Cheng Yeh
RLRichard Lai
Richard Lai
RBRoss Thomas Barnard
Ross Thomas Barnard
In this unit, we describe a multiplex microsphere quantitative PCR. The system is based on the use of two additional oligonucleotides within a single tube PCR reaction. The first oligonucleotide is modified with a single base pair mismatch and is otherwise equivalent to a universal sequence added to the forward PCR primer. Further, this first extra oligonucleotide is coupled to Luminex microspheres. The second additional oligonucleotide is designed to be complementary to the universal sequence, and is modified with the fluorescent dye Cy3. As the PCR reaction proceeds, the second oligonucleotide is able to bind to the microspheres. Thus, quantitative monitoring of PCR progress takes place. The microsphere‐mediated Cy3‐detection is measured using flow cytometry directly after the PCR reaction. This allows a flow cytometer analysis from up to 150 different spheres and, therefore, multiple genes in one reaction. The multiplex microsphere qPCR is demonstrated using three target genes from Influenza A and Neisseria meningitidis. The multiplex microsphere system will enable a higher degree of multiplexing than is possible with currently available qPCR systems. Curr. Protoc. Cytom. 69:13.13.1‐13.13.10. © 2014 by John Wiley & Sons, Inc.